Following up on their discussion of COVID-19 vaccines and therapeutics, Venrock partner Bryan Roberts speaks with Mathai Mammen, Global Head of R&D at the Janssen Pharmaceutical Companies of Johnson & Johnson, about Mammen’s career path and what differences he’s found working on drug development in both small companies and large companies. Managing 14,000 people has its challenges, but the scale is incredible: J&J’s products touch more than 1 billion people worldwide. They also discuss trends in gene editing and CRISPR thanks to machine learning and AI.
Venrock partner Bryan Roberts chats with Mathai Mammen about COVID-19 vaccine development and therapeutics in this special episode of Running Through Walls. Mammen serves as the Global Head of R&D at the Janssen Pharmaceutical Companies of Johnson & Johnson, where he is heading up the firm’s COVID-19 vaccine development. They discuss J&J’s unique approach to the vaccine and which therapeutics are promising in the fight against the virus. Mammen shares how the U.S. can be better prepared for the next pandemic, and highlights how his company approaches vaccine production and distribution on a global scale.